Article Text

Download PDFPDF
Dentatorubral-pallidoluysian atrophy: a rare cause of epilepsy, ataxia and chorea
  1. Karthik Harisankar,
  2. Jagdeep Singh,
  3. Sahil Mehta,
  4. Vivek Lal
  1. Post Graduate Institute of Medical Education and Research, Chandigarh, India
  1. Correspondence to Dr Sahil Mehta, Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India; mehtasahilpgi{at}gmail.com

Abstract

A 34-year-old woman presented with insidious onset and gradually progressive cerebellar ataxia over 10 years, with generalised convulsions. On examination, there were myoclonic jerks, choreiform movements and cerebellar syndrome. Her family history suggested an autosomal dominant inheritance with anticipation. Genetic analysis for trinucleotide repeat disorders led to a diagnosis of dentatorubral-pallidoluysian atrophy (60 CAG repeats in the atrophin-1 gene). This rare spinocerebellar ataxia should be considered in the differential diagnosis of inherited ataxia when combined with seizures and chorea. Other features suggesting a repeat expansion disorder are variable phenotypes within the same family and possible anticipation.

  • EPILEPSY
  • CEREBELLAR ATAXIA
  • MOVEMENT DISORDERS

Data availability statement

Data are available on reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available on reasonable request.

View Full Text

Footnotes

  • X @mehtasahilpgi

  • Contributors SM conceived the report, managed the patient, revised the draft and edited the videos. KH wrote the first draft and edited the figures. JS collected all the patient data. VL revised the manuscript. SM is the guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally reviewed by Zhongbo Chen, London, UK.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.